IL8 and cathepsin B as melanoma serum biomarkers

International Journal of Molecular Sciences

Volumn 12, Issue 3, 2011, Pages 1505-1518

  Zhang, Hongtao ^a   Fu, Ting ^a   Mcgettigan, Suzanne ^b   Kumar, Suresh ^a   Liu, Shujing ^a   Speicher, David ^c   Schuchter, Lynn ^b   Xu, Xiaowei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Division of Hematology Oncology   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Cathepsin B; IL 8; Melanoma; Serum interference

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN B; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MONOPHENOL MONOOXYGENASE; CYTOKINE; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MELANOMA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; BREAST TUMOR; CANCER STAGING; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL;

AGED; BREAST NEOPLASMS; CATHEPSIN B; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM STAGING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953327929     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12031505     Document Type: Article

References (32)

1. Tsao, H.; Atkins, M.B.; Sober, A.J. Management of cutaneous melanoma. N. Engl. J. Med. 2004, 351, 998-1012.
2. Weinstock, M.A. Progress and prospects on melanoma: the way forward for early detection and reduced mortality. Clin. Cancer Res. 2006, 12, 2297s-2300s.
3. Xu, X.; Zhang, P.J.; Elder, D.E. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch. Pathol. Lab. Med. 2003, 127, 1084-1085.
4. Karnell, R.; Kagedal, B.; Lindholm, C.; Nilsson, B.; Arstrand, K.; Ringborg, U. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res. 2000, 10, 363-369.
5. Murakami, K.; Wakamatsu, K.; Nakanishi, Y.; Takahashi, H.; Sugiyama, S.; Ito, S. Serum levels of pigmentation markers are elevated in patients undergoing hemodialysis. Blood Purif. 2007, 25, 483-489.
6. Bolander, A.; Agnarsdottir, M.; Wagenius, G.; Stromberg, S.; Ponten, F.; Ekman, S.; Brattstrom, D.; Larsson, A.; Einarsson, R.; Ullenhag, G.; et al. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res. 2008, 18, 412-419.
7. Linette, G.P.; Carlson, J.A.; Slominski, A.; Mihm, M.C.; Ross, J.S. Biomarkers in melanoma: stage III and IV disease. Expert Rev. Mol. Diagn. 2005, 5, 65-74.
8. Ugurel, S.; Utikal, J.; Becker, J.C. Tumor biomarkers in melanoma. Cancer Control 2009, 16 219-224.
9. Liotta, L.A.; Ferrari, M.; Petricoin, E. Clinical proteomics: written in blood. Nature 2003, 425, 905.
10. Longo, C.; Gambara, G.; Espina, V.; Luchini, A.; Bishop, B.; Patanarut, A.S.; Petricoin, E.F., III; Beretti, F.; Ferrari, B.; Garaci, E.; et al. A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp. Dermatol. 2011, 20, 29-34.
11. Zhang, H.; Cheng, X.; Richter, M.; Greene, M.I. A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat. Med. 2006, 12, 473-477.
12. Kricka, L.J. Human anti-animal antibody interferences in immunological assays. Clin. Chem. 1999, 45, 942-956.
13. Maher, V.E.; Drukman, S.J.; Kinders, R.J.; Hunter, R.E.; Jennings, J.; Brigham, C.; Stevens, S.; Griffin, T.W. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody. J. Immunother. (1991) 1992, 11, 56-66.
14. Andersen, D.C.; Koch, C.; Jensen, C.H.; Skjodt, K.; Brandt, J.; Teisner, B. High prevalence of human anti-bovine IgG antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies. J. Immunoassay Immunochem. 2004, 25, 17-30.
15. Reinsberg, J. Different efficacy of various blocking reagents to eliminate interferences by human antimouse antibodies with a two-site immunoassay. Clin. Biochem. 1996, 29, 145-148.
16. Yu, A.; Pira, U. False increase in serum C-reactive protein caused by monoclonal IgM-lambda: a case report. Clin. Chem. Lab. Med. 2001, 39, 983-987.
17. Larsson, A.; Wejaker, P.E.; Forsberg, P.O.; Lindahl, T. Chicken antibodies: a tool to avoid interference by complement activation in ELISA. J. Immunol. Methods 1992, 156, 79-83.
18. Grebenchtchikov, N.; Sweep, C.G.; Geurts-Moespot, A.; Piffanelli, A.; Foekens, J.A.; Benraad, T.J. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J. Immunol. Methods 2002, 268, 219-231.
19. Scheibenbogen, C.; Mohler, T.; Haefele, J.; Hunstein, W.; Keilholz, U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res. 1995, 5, 179-181.
20. Brennecke, S.; Deichmann, M.; Naeher, H.; Kurzen, H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res. 2005, 15, 515-522.
21. Tang, H.-Y.; Echan, L.A.; Tan, G.C.; Joo, W.-A.; Kumar, S.; Schuchter, L.; Xu, X.; Speicher, D.W. Identification of candidate human metastatic melanoma biomarkers using a xenograft mouse model and a three-dimensional protein profiling strategy. Unpublished work, 2011.
22. Leach, M.F.; Aubuchon, J.P. False reactivity in GTI Pak Plus ELISA kits due to the presence of anti-mouse antibody in patients' samples. Immunohematol 2003, 19, 112-116.
23. Gocheva, V.; Zeng, W.; Ke, D.; Klimstra, D.; Reinheckel, T.; Peters, C.; Hanahan, D.; Joyce, J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20, 543-556.
24. Korner, A.; Pawelek, J. Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin. Science 1982, 217, 1163-1165.
25. Tripathi, P.C.; Tripathi, R.C. Analysis of glycoprotein deposits on disposable soft contact lenses. Invest. Ophthalmol. Visual Sci. 1992, 33, 121-125.
26. Schadendorf, D.; Moller, A.; Algermissen, B.; Worm, M.; Sticherling, M.; Czarnetzki, B.M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 1993, 151, 2667-2675.
27. Mashiah, J.; Brenner, S.; Pessach, Y.; Barak, V.; Schachter, J. Differences in cytokine levels in melanoma patients with and without redness (Brenner sign). Anticancer Res. 2009, 29, 1793-1796.
28. Huang, S.; Mills, L.; Mian, B.; Tellez, C.; McCarty, M.; Yang, X.D.; Gudas, J.M.; Bar-Eli, M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002, 161, 125-134.
29. Yurkovetsky, Z.R.; Kirkwood, J.M.; Edington, H.D.; Marrangoni, A.M.; Velikokhatnaya, L.; Winans, M.T.; Gorelik, E.; Lokshin, A.E. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin. Cancer Res. 2007, 13, 2422-2428.
30. Linebaugh, B.E.; Sameni, M.; Day, N.A.; Sloane, B.F.; Keppler, D. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. 1999, 264, 100-109.
31. Gondi, C.S.; Lakka, S.S.; Dinh, D.H.; Olivero, W.C.; Gujrati, M.; Rao, J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004, 23, 8486-8496.
32. Schraufstatter, I.U.; Trieu, K.; Zhao, M.; Rose, D.M.; Terkeltaub, R.A.; Burger, M. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J. Immunol. 2003, 171, 6714-6722.